Eterna Therapeutics logo

Eterna TherapeuticsNASDAQ: ERNA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 August 1991

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.63 M
-98%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-101%vs. 3y high
13%vs. sector
-85%vs. 3y high
89%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.04-$0.05(-4.59%)

Dividend

No data over the past 3 years
$47.00 K-$5.53 M

Analysts recommendations

Institutional Ownership

ERNA Latest News

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
globenewswire.com30 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success.

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
globenewswire.com17 October 2024 Sentiment: POSITIVE

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor's cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.

What type of business is Eterna Therapeutics?

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

What sector is Eterna Therapeutics in?

Eterna Therapeutics is in the Healthcare sector

What industry is Eterna Therapeutics in?

Eterna Therapeutics is in the Biotechnology industry

What country is Eterna Therapeutics from?

Eterna Therapeutics is headquartered in United States

When did Eterna Therapeutics go public?

Eterna Therapeutics initial public offering (IPO) was on 29 August 1991

What is Eterna Therapeutics website?

https://eternatx.com

Is Eterna Therapeutics in the S&P 500?

No, Eterna Therapeutics is not included in the S&P 500 index

Is Eterna Therapeutics in the NASDAQ 100?

No, Eterna Therapeutics is not included in the NASDAQ 100 index

Is Eterna Therapeutics in the Dow Jones?

No, Eterna Therapeutics is not included in the Dow Jones index

When was Eterna Therapeutics the previous earnings report?

No data

When does Eterna Therapeutics earnings report?

The next expected earnings date for Eterna Therapeutics is 13 November 2024